After decades of procedures and millions upon millions of implant recipients, the FDA has formalized procedures that, among other things, now require patient notification of the potential risks and complications that come with breast augmentation surgery.
The move comes after several cases of breast implant-associated large cell lymphoma were reported in primarily European markets. Initially thought to be tied to the textured implants used mostly by European doctors, focus ...
continue reading...
